US CDC to expand surveillance of traveler samples for respiratory
viruses
Send a link to a friend
[November 07, 2023]
(Reuters) -The U.S. Centers for Disease Control and Prevention
(CDC) said on Monday it was expanding testing of samples collected from
international air travelers beyond COVID-19, to include flu and
respiratory synctial virus (RSV) beginning November.
The agency's traveler-based genomic surveillance program, or TGS, began
in 2021 to help with early detection of new SARS-CoV-2 variants. CDC
conducts voluntary nasal swabbing and airport wastewater sampling as
part of it.
The program includes seven participating international airports across
the country - Los Angeles, New York's John F. Kennedy, San Francisco,
Boston Logan, Washington Dulles, Seattle and Newark.
"Our focus is always on airports that are international hubs and have
flights coming in from a broad array of international locations so we
can get a picture of what's going on globally and detect concerning
strains early," said Cindy Friedman Chief of CDC's Travelers' Health
Branch.
Of the 6,000 nasal swab samples collected every week under the program,
about 2,000 are tested for respiratory diseases, Friedman said, adding
that nasal swabs from two of seven participating airports have been
tested since October.
[to top of second column]
|
A general view of the Centers for Disease Control and Prevention
(CDC) headquarters in Atlanta, Georgia September 30, 2014.
REUTERS/Tami Chappell/File Photo
Wastewater sampling from some of the
airports began in November, Friedman added without providing details
of the locations.
The pilot expansion, which will last for several
months, comes ahead of the U.S. winter months when
respiratory-disease causing viruses usually circulate more heavily.
CDC has warned that it expects hospitalizations from COVID-19, RSV
infections and flu this year to be similar to last year's numbers,
higher than the pre-pandemic levels.
TGS is a public-private partnership between the health agency, and
the expansion project is being implemented by biotech company Ginkgo
Bioworks and wellness holding company XWELL.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini
Ganguli)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |